DPP-4 inhibitors and COVID-19 outcomes

Share this article

+ Add to reading list – Remove from reading list

The French CORONADO study provides reassuring data about the safety of dipeptidyl peptidase-4 inhibitors in the context of the pandemic, and suggests that prescribing practice need not be changed.

Click here to read our summary.

Draft NICE recommendations on hybrid closed-loop systems set to change lives

EMPA-KIDNEY trial shows benefits of empagliflozin in CKD

Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK

PCDS consensus statement: A strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity

Dual GIP/GLP-1 receptor agonist tirzepatide receives MHRA marketing authorisation

Dexcom G7 rtCGM device launched

EASD 2022: Updated ADA/EASD type 2 diabetes consensus published

Related content

Draft NICE recommendations on hybrid closed-loop systems set to change lives

Many more with type 1 diabetes set to benefit from new technology following publication of draft guidance.

18 Jan 2023

EMPA-KIDNEY trial shows benefits of empagliflozin in CKD

Reduced risk of renal progression and cardiovascular death in a wide range of people with CKD, with eGFR as low as 20.

18 Nov 2022

Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK

STIMULAN placed in foot wounds following debridement can release antibiotics at therapeutic concentrations

4 Nov 2022

PCDS consensus statement: A strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity

A strategy for safely switching to alternative agents within the GLP-1 RA class if stocks are limited.

14 Oct 2022

For the latest news and articles

Resources

Journals

Useful information

;